OOIR: Observatory of International Research

Papers

(The median citation count of Therapeutic Advances in Hematology is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Monocyte or white blood cell counts and β₂ microglobulin predict the durable efficacy of daratumumab with lenalidomide	28
BEST study: one-year descriptive follow-up of bevacizumab treatment in hereditary haemorrhagic telangiectasia post-BABH interventional study	27
The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria	27
Prognostic impact of IL7R mutations on acute myeloid leukemia	27
Effective engraftment via granulocyte transfusion in pre-engraftment febrile neutropenia following allogeneic hematopoietic stem cell transplantation: granulocyte transfusion as bridge therapy	24
Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine	24
Brain iron content and cognitive function in patients with β-thalassemia	22
Successful maintenance of a sustained molecular response in CML patients receiving low-dose tyrosine kinase inhibitors	21
Treatment of multiple myeloma: What is the impact on T-cell function?	20
Macrofocal multiple myeloma in the era of novel agents in China	19
Role of abatacept in the prevention of graft-versus-host disease: current perspectives	19
A comparison of the effect of three different comorbidity indices on overall survival in patients with chronic myeloid leukemia	18
Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma	15
Comparison of eltrombopag and avatrombopag in the treatment of refractory/relapsed aplastic anemia: a single-center retrospective study in China	15
Outcomes of patients with diffuse large B-cell and high-grade B-cell lymphomas with synchronous CNS and systemic involvement at diagnosis treated with high-dose methotrexate and R-CHOP: a single-cente	15
Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes	15
Safety and efficacy of luspatercept in treating anemia associated with myelodysplastic syndrome with ring sideroblasts in Asian patients who require red blood cell transfusions: a phase II bridging st	13
How to translate and implement the current science of gene therapy into haemophilia care?	13
The role of surveillance computed tomography in patients with follicular lymphoma	13
Real-world usage and effectiveness of recombinant factor IX Fc in haemophilia B from the B-SURE study in France	13
Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B: post hoc analysis of phase III	13
Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ⩾2 tyrosine kinase inhibitors: a systematic literature review	13
Thanks to Reviewers	12
Successful rechallenge with Erwinia chrysanthemi asparaginase after pegaspargase-induced hypertriglyceridemia: a case report	12
Use and positioning of fostamatinib in the management of primary chronic immune thrombocytopenia: an Italian expert opinion	11

Advancements in minimal residual disease detection: a practical approach using single-cell droplet PCR for comprehensive monitoring in hematological malignancy	11
Efficacy and safety of anti-CD38 monoclonal antibodies-based therapy versus standard therapy in newly diagnosed multiple myeloma patients: a systematic review and meta-analysis	10
Cardiovascular-specific mortality among multiple myeloma patients: a population-based study	10
Anemia is associated with long-term exposure to PM_2.5 and its components: a large population-based study in Southwest China	10
Toxicity management strategies for next-generation novel therapeutics in multiple myeloma	9
Corrigendum to “Real-world use of recombinant porcine sequence factor VIII in the treatment of acquired hemophilia A: EU PASS”	9
Association of CVAI, LAP and SMI with risk of haematological toxicity after immunochemotherapy in patients with DLBCL: a retrospective study	9
A new beginning: can omidubicel emerge as the next, viable alternative donor source?	9
Mantle cell lymphoma management trends and novel agents: where are we going?	9
Non-invasive prenatal testing for fetal Ss, Kidd, and CTL2 blood group prediction by multiplex digital droplet PCR	9
A systematic review and meta-analysis of carfilzomib-associated thrombocytopenia as an adverse event in patients with multiple myeloma	8
Assessment of risk factors for acute graft-versus-host disease post-hematopoietic stem cell transplantation: a retrospective study based on a proportional odds model using a nonlinear mixed-eff	8
Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors	8
Avatrombopag treatment response in patients with immune thrombocytopenia: the REAL-AVA 1.0 study	8
Calculated haemorheological profile and laboratory parameters in new diagnosed multiple myeloma patients: retrospective analysis according to survival	8
Between Charybdis and Scylla—an Odyssey in AL amyloidosis: insights and learnings from a narrative review and case report series	8
Efficacy of complement inhibitors for patients with paroxysmal nocturnal hemoglobinuria: a systematic review and meta-analysis	8
Efficacy and safety of venetoclax-based regimens for the treatment of relapsed/refractory multiple myeloma: a systemic review and meta-analysis	8
Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia	8
Interferons in the treatment of myeloproliferative neoplasms	8
Superior survival outcome of blinatumomab compared with conventional chemotherapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia: a propensity score–match	8
Circulating HMGB1 is increased in myelodysplastic syndrome but not in other bone marrow failure syndromes: proof-of-concept cross-sectional study	7
Current state of CAR-T therapy for T-cell malignancies	7
Demographics, clinical characteristics, and real-world treatment patterns among patients with beta-thalassemia: a retrospective medical record abstraction study	7
Application and investigation of thrombopoiesis-stimulating agents in the treatment of thrombocytopenia	7
Prognostic significance of MRD and its correlation with arsenic concentration in pediatric acute promyelocytic leukemia: a retrospective study by SCCLG-APL group	7
Single-center experience of venetoclax combined with azacitidine in young patients with newly diagnosed acute myeloid leukemia	7
Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry	7
Antihuman T lymphocyte porcine immunoglobulin combined with cyclosporine as first-line immunosuppressive therapy for severe aplastic anemia in China: a large single-center, 10-year retrospective study	7
Targeting an elevated FVIII level using personalized rurioctocog alfa pegol prophylaxis in specific patient populations with hemophilia A: post hoc subanalysis of the randomized, phase 3 PROPEL	6
Risk factors and prognosis of thrombocytopenia in people living with HIV/AIDS	6
CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma	6
Rilzabrutinib versus placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III study	6
Outpatient allogeneic hematopoietic stem-cell transplantation: a review	5
Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease: final results from the phase II SOLACE-adults study	5
Avatrombopag for the salvage treatment of platelet transfusion refractoriness	5
A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML)	5
Advancing the standard: venetoclax combined with intensive induction and consolidation therapy for acute myeloid leukemia	5
Predicting cytomegalovirus infection and graft-versus-host disease using QuantiFERON-CMV and Monitor in pediatric transplants: a proof-of-concept study	5
Mechanisms of resistance to histone deacetylase inhibitors in acute leukemia	5
Relapsed/refractory pure red cell aplasia in chronic lymphocytic leukemia successfully treated with acalabrutinib: a case report and review of the literature	5
Is less more? Intravenous immunoglobulin for pediatric immune thrombocytopenia	5
Research advances on short-chain fatty acids in gastrointestinal acute graft-versus-host disease	5
Treatment of multiple myeloma with selinexor: a review	5
Significance of whole-blood EBV DNA status in T/NK-cell lymphoma-associated hemophagocytic lymphohistiocytosis: a single-center retrospective analysis	5
Development of a nomogram to predict the risk of secondary failure of platelet recovery in patients with β-thalassemia major after hematopoietic stem cell transplantation: a retrospective study	4
Major cardiac surgery with recombinant FIX Fc fusion protein replacement in hemophilia B: a case report	4
Vedolizumab for second-line treatment of steroid-refractory gastrointestinal late acute graft-versus-host disease	4
Recent advances in CAR-T therapy for the treatment of acute myeloid leukemia	4
Durable outcomes of double cord blood transplantation in adults with acute lymphoblastic leukemia: high-risk features for early and long-term mortality	4

Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria	4
Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in hematologic malignancies: a living systematic review on comparative studies	4
An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment	3
Progress and prospect of ASCT combined with CAR-T therapy in the treatment of multiple myeloma	3
Improved survival outcomes with anakinra over etoposide-based therapies for the management of adults with hemophagocytic lymphohistiocytosis: a retrospective multicenter research network study	3
Systematic literature review of the indirect costs and humanistic burden of β-thalassemia	3
The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia	3
An occurrence of eosinophilic folliculitis and alopecia associated with a sustained complete response to mogamulizumab in Sézary syndrome: a case report	3
Design of an international, phase IV, open-label study of simoctocog alfa in women/girls with hemophilia A undergoing surgery (NuDIMENSION)	3
Effect of BCR::ABL1 transcript type and droplet digital polymerase chain reaction on successful treatment-free remission in chronic myeloid leukemia patients who discontinued tyrosine kinase in	3
Diagnosis and management of multiple myeloma during pregnancy: case report, review of the literature, and an update on current treatments	3
Prednisone plus IVIg compared with prednisone or IVIg for immune thrombocytopenia in pregnancy: a national retrospective cohort study	3
Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma	3
Clinical features and treatment of newly diagnosed multiple myeloma with secondary myelofibrosis: a retrospective study	3
Recent advances in immunotherapy for B-cell non-Hodgkin lymphoma and multiple myeloma	2
A phase I trial of pevonedistat in combination with ruxolitinib for the treatment of myelofibrosis	2
The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma	2
When idiopathic multicentric Castleman disease meets COVID-19: a multicenter retrospective study from China	2
Infrastructural considerations of implementing gene therapy for hemophilia in the Nordic context	2
Genetic lesions and targeted therapy in Hodgkin lymphoma	2
Iron overload status in patients with non-transfusion-dependent thalassemia in China	2
A nomogram based on InLDH and InNLR for predicting disseminated intravascular coagulation in patients with heat stroke	2
Real-world patient characteristics and treatment patterns of polycythemia vera in Taiwan between 2016 and 2017: a nationwide cross-sectional study	2
Efficacy and safety of avatrombopag in the treatment of chemotherapy-induced thrombocytopenia in children with acute lymphoblastic leukemia: a single-center retrospective study	2
Improvement in pain-related quality of life in patients with hemophilia A treated with rFVIIIFc individualized prophylaxis: post hoc analysis from the A-LONG study	2
The efficacy and safety of third-party umbilical blood/umbilical cord mesenchymal stem cell assisted related haploid hematopoietic stem cell transplantation in pediatric patients with acute leukemia:	2
Experience in the management of patients with HTLV-1 positive adult T-cell leukemia/lymphoma in a Latin American center	2
Efficacy of emicizumab in patients with severe haemophilia A without factor VIII inhibitors in Germany: evaluation of real-life data documented by the smart medication eDiary	2
Cost-effectiveness of acalabrutinib monotherapy or with obinutuzumab versus chemoimmunotherapy for untreated chronic lymphocytic leukemia in China	2
Outcomes and management of invasive procedures in participants with hemophilia A post gene therapy: a post hoc analysis of the GENEr8-1 phase III trial	2
Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study	2
Recent advances of CAR-T cells in acute myeloid leukemia	2
Cost-effectiveness analysis of axicabtagene ciloleucel as a second-line treatment for diffuse large B-cell lymphoma in China and the United States	2
Real-world use of recombinant porcine sequence factor VIII in the treatment of acquired hemophilia A: EU PASS	2
Next-generation sequencing of circulating tumor DNA in cerebrospinal fluid for detecting gene mutations in central nervous system lymphoma patients	2
MYD88^L265P and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy	2